EBS
Emergent Biosolutions Inc
NYSE · Biotechnology
$10.92
+0.38 (+3.61%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.03B | 1.24B | 343.48M | 356.03M | 320.59M |
| Net Income | -188,872,292 | -203,574,925 | -73,282,630 | -80,261,545 | -61,575,433 |
| EPS | — | — | — | — | — |
| Profit Margin | -18.3% | -17.4% | -21.3% | -22.5% | -19.2% |
| Rev Growth | -16.5% | -16.5% | +21.6% | +7.9% | +14.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 166.00M | 166.00M | 100.53M | 108.79M | 90.00M |
| Total Equity | 120.76M | 120.76M | 306.35M | 281.81M | 307.34M |
| D/E Ratio | 1.37 | 1.37 | 0.33 | 0.39 | 0.29 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -6,738,311 | -7,666,341 | -100,144,769 | -95,339,299 | -103,196,575 |
| Free Cash Flow | — | — | -51,592,821 | -67,766,487 | -48,928,891 |